Reduction of Morbidity and Mortality by Statins, Angiotensin-Converting Enzyme Inhibitors, and Angiotensin Receptor Blockers in Patients With Chronic Obstructive Pulmonary Disease

Journal of the American College of Cardiology

Volumn 47, Issue 12, 2006, Pages 2554-2560

  Mancini, G B John ^a   Etminan, Mahyar ^a   Zhang, Bin ^b   Levesque, Linda E ^b   FitzGerald, J Mark ^a   Brophy, James M ^b  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; NONSTEROID ANTIINFLAMMATORY AGENT; THEOPHYLLINE;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONFIDENCE INTERVAL; FEMALE; HEART DISEASE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEART PROTECTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT OUTCOME;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COHORT STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, ANGIOTENSIN; RETROSPECTIVE STUDIES;

EID: 33744994082     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2006.04.039     Document Type: Article

References (32)

1. Rennard S.I. Treatment of stable chronic obstructive pulmonary disease. Lancet 364 (2004) 791-802
2. Rauwels R.A., Buist S., Calverley P.M.A., Jenkins C.R., Hurd S.S., and GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 163 (2001) 1256-1276
3. Sin D.D., Wu L., Anderson J.A., et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 60 (2005) 992-997
4. Friedman G.D., Klatsky A.L., and Siegelaub A.B. Lung function and risk of myocardial infarction and sudden cardiac death. N Engl J Med 294 (1976) 1071-1075
5. Schunemann H.J., Dorn J., Grant B.J.B., Winkelstein W., and Trevisan M. Pulmonary function is a long-term predictor of mortality in the general population. 29-year follow-up of the Buffalo Health Study. Chest 118; (2000) 656-664
6. Hole D.J., Watt G.C.M., Davey-Smith G., Hart C.L., Gillis C.R., and Hawthorne V.M. Impaired lung function and mortality risk in men and women. findings from the Renfrew and Paisley prospective population study. Br Med J 313 (1996) 711-715
7. Kizer J.R., Zisman D.A., Blumenthal N.P., et al. Association between pulmonary fibrosis and coronary artery disease. Arch Intern Med 164 (2004) 551-556
8. Benowitz N.L. Cigarette smoking and cardiovascular disease. pathophysiology and implications for treatment. Prog Cardiovasc Dis 46 (2003) 91-111
9. Samet J.M., Dominici F., Curriero F.C., Coursac I., and Zeger S.L. Fine particulate air pollution and mortality in 20 U.S. cities, 1987-1994. N Engl J Med 343 (2000) 1742-1749
10. Pope III C.A., Burnett R.T., Thun M.J., et al. Lung cancer, cardiopulmonary mortality, and long-term exposure to fine particulate air pollution. JAMA 287 (2002) 1132-1141
11. Mancini G.B.J. The "double dip" hypothesis. simultaneous prevention of cardiovascular and pulmonary morbidity and mortality using angiotensin II type 1 receptor blockers. Can J Cardiol 21 (2005) 519-523
12. Mancini G.B.J., and Khalil N. Angiotensin II type 1 receptor blocker inhibits pulmonary injury. Clin Invest Med 28 (2005) 118-126
13. Otsuka M., Takahashi H., Shiratori M., Chiba H., and Abe S. Reduction of bleomycin induced lung fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonist. Thorax 59 (2004) 31-38
14. Jacobson J.R., Barnard J.W., Grigoryev D.N., Ma S.-F., Tuder R.M., and Garcia J.G.N. Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury. Am J Physiol Lung Cell Mol Physiol 288 (2005) L1026-L1032
15. Marshall R.P., McAnulty R.J., and Laurent G.J. Angiotensin II is mitogenic for human lung fibroblasts via activation of the type 1 receptor. Am J Respir Crit Care Med 161 (2000) 1999-2004
16. 1 mediates alveolar epithelial cell apoptosis in response to ANG II. Am J Physiol Lung Cell Mol Physiol 282 (2002) L713-L718
17. Li X., Zhang H., Soledad-Conrad V., Zhuang J., and Uhal B.D. Bleomycin-induced apoptosis of alveolar epithelial cells requires angiotensin synthesis de novo. Am J Physiol Lung Cell Mol Physiol 284 (2003) L501-L507
18. Kothe H., Dalhoff K., Rupp J., et al. Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae. Circulation 101 (2000) 1760-1763
19. Girgis R.E., Li D., Zhan X., et al. Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Heart Circ Physiol 285 (2003) H938-H945
20. Fessler M.B., Young S.K., Jeyaseelan S., et al. A role for hydroxyl-methylglutaryl coenzyme A reductase in pulmonary inflammation and host defense. Am J Respir Crit Care Med 171 (2005) 606-615
21. Ward W.F., Molteni A., Ts'ao C., Kim Y.T., and Hinz J.M. Radiation pneumotoxicity in rats. modification by inhibitors of angiotensin converting enzyme. Int J Radiat Oncol Biol Phys 22 (1992) 623-625
22. Candan F., and Algozlu H. Captopril inhibits the pulmonary toxicity of paraquat in rats. Hum Exp Toxicol 20 (2001) 637-641
23. Molteni A., Moulder J.E., Cohen E.F., et al. Control of radiation-induced pneumopathy and lung fibrosis by angiotensin-converting enzyme inhibitors and an angiotensin II type 1 receptor blocker. Int J Radiat Biol 76 (2000) 523-532
24. Uhal B.D., Wang R., Laukka J., Zhuang J., Soledad-Conrad V., and Filippatos G. Inhibition of amiodarone-induced lung fibrosis but not alveolitis by angiotensin system antagonists. Pharmacol Toxicol 92 (2003) 81-87
25. Brophy J.M., Bourgault C., and Brassard P. The use of cholesterol-lowering medications after coronary revascularization. Can Med Assoc J 169 (2003) 1153-1157
26. Levesque L., Brophy J.M., and Zhang B. The risk of myocardial infarction with cyclooxygenase-2 inhibitors. a population study of elderly adults. Ann Int Med 142 (2005) 481-489
27. Suissa S., Assimes T., and Enrst P. Inhaled short acting beta agonist use in COPD and risk of acute myocardial infarction. Thorax 58 (2003) 44-46
28. Essebag V., Genest Jr. J., Suissa S., and Pilote L. The nested case-control study in cardiology. Am Heart J 146 (2003) 581-590
29. Peters A., Dockery D.W., Muller J.E., and Mittleman M.A. Increased particulate air pollution and the triggering of myocardial infarction. Circulation 103 (2001) 2810-2815
30. Suwa T., Hogg J.C., Quinlan K.B., Ohgami A., Vincent R., and van Eeden S.F. Particulate air pollution induces progression of atherosclerosis. J Am Coll Cardiol 39 (2002) 935-942
31. Sin D.D., and Man S.F.P. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases?. The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 107 (2003) 1514-1519
32. Barnes P.J., and Hansel T.T. Prospects for new drugs for chronic obstructive pulmonary disease. Lancet 364 (2004) 985-996